Clinical outcomes of allogeneic hematopoietic stem cell transplantation from matched sibling donor for myelofibrosis
10.3760/cma.j.cn112138-20240409-00225
- VernacularTitle:同胞相合异基因造血干细胞移植治疗骨髓纤维化的临床观察
- Author:
Rui MA
1
;
Borui TANG
;
Tingting HAN
;
Xueyi LUO
;
Wei HAN
;
Yao CHEN
;
Xiaodong MO
;
Lanping XU
;
Xiaohui ZHANG
;
Yu WANG
;
Xiaojun HUANG
;
Yuqian SUN
Author Information
1. 北京大学人民医院 北京大学血液病研究所 造血干细胞移植治疗血液病北京市重点实验室，北京 100044
- Keywords:
Myelofibrosis;
Allogeneic hematopoietic stem cell transplantation;
Matched sibling donor
- From:
Chinese Journal of Internal Medicine
2024;63(10):961-967
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of myelofibrosis (MF).Methods:In this case series, the clinical data of 18 patients with MF who received allo-HSCT in the Department of Hematology, Peking University People′s Hospital from December 2008 to December 2023 were retrospectively studied. Kaplan-Meier survival analysis and competitive risk model were used to evaluate the probabilities of 3-year overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), and transplant related mortality (TRM). The transplant related complications were also analyzed.Results:Among the 18 patients included, there were 12 males and 6 females, with a median age of 50 (range: 28-64) years. All 18 patients achieved neutrophil engraftment, and the time of neutrophil engraftment [ M ( Q1, Q3)] was 16.0 (11.8, 18.0) days. Twelve patients achieved platelet engraftment, and the platelet engraftment time was 21.0 (16.2, 43.2) days. Six patients had grade Ⅱ to Ⅳ acute graft-versus-host disease (GVHD), and six patients had chronic GVHD. The 3-year OS rate and DFS rate after transplantation were 62.2% and 52.2%, respectively. The 3-year CIR and TRM were 29.7% and 24.6%, respectively. Four patients died during follow-up, with the main cause of death being infections. Conclusion:Matched sibling allo-HSCT is a feasible option for the treatment of MF.
